This Week in Review

After Sessions Takes Off the Gloves, the Legalized Cannabis Industry Strikes Back, Experts and Politicians Weigh in on Potential Impact, GW Pharmaceuticals Inches Closer to FDA Approval of CBD Medicine

After Sessions Takes Off the Gloves, the Legalized Cannabis Industry Strikes Back

While the gloves are off, it's unclear who will be throwing the first punch: United States Attorney General Jeff Sessions or the legalized cannabis industry. In this morning's attached internal guidance to all United States Attorneys entitled "Marijuana Enforcement," Mr. Sessions rescinded some of his office's prior guidelines instructing that, like its predecessors, his guidance creates no "rights, substantive or procedural, enforceable at law by any party in any matter civil or criminal." Read more

What now? Experts and politicians weigh in on potential impact of Sessions’ rollback of marijuana policy

Days after California became the largest U.S. state to initiate regulated sales of cannabis to adults, a wave of uncertainty has crashed over America’s cannabis industry with the Justice Department’s elimination of Obama-era guidance on marijuana enforcement. Read more

GW Pharmaceuticals Inches Closer to FDA Approval of CBD Medicine

FDA has accepted for filing a New Drug Application (NDA) submitted by GW Pharmaceuticals plc, moving the biopharmaceutical company closer to marketing a drug containing CBD to treat two rare forms of epilepsy resistant to treatments: Lennox-Gastaut syndrome (LGS) and Dravet syndrome. Read more

Eight marijuana operators set to grow; 10,000 patients registered

More than 10,000 patients have registered with Pennsylvania’s medical marijuana program, Gov. Wolf announced Wednesday, with nearly 1,200 of those patients certified by a physician to participate. In a statement heavy on numbers, Wolf also said that eight medical marijuana growers have been approved to start cultivating their first crops. Read more